Tech Transfer In CDMOs: Avoiding The Scale-Up Trap

Tech transfer at a contract development and manufacturing organization (CDMO) is less a handover than a stress test, and the gap between lab-ready and plant-ready is where most scale-up failures quietly begin. The scale-up trap isn't usually one catastrophic event. It shows up as slow filtrations, unstable phase splits, or an impurity that was negligible at bench scale and becomes a real problem at plant scale.
The core issue is that many development packages are complete only for the lab that built them. A different solvent grade, a different filter area, a different sampling quench, and your impurity profile can shift in ways that weren't obvious until manufacturing was already underway. Mixing dynamics don't translate linearly across vessel sizes. Heat removal becomes limiting in ways that change kinetics and sometimes selectivity. Local concentration spikes in fast reactions can produce entirely different impurity families.
Strong chemical process development reframes these as design signals rather than operational noise. That means defining success at scale upfront, including target yield, impurity profile, and critical process parameter ranges, then mapping what must stay fixed and what proof is required before any change is accepted. The goal is a process that is repeatable, auditable, and resilient to normal manufacturing variability before the first batch, not after. Access the full analysis to understand which development gaps create the most risk during CDMO tech transfer.
Get unlimited access to:
Enter your credentials below to log in. Not yet a member of Bioprocess Online? Subscribe today.